Kiniksa Pharmaceuticals, Ltd. Forecasted to Earn Q2 2024 Earnings of ($0.06) Per Share (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities researchers at Wedbush increased their Q2 2024 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals in a report released on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.16). Wedbush has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.06) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.02 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2027 earnings at $1.26 EPS.

KNSA has been the topic of a number of other reports. Evercore ISI raised their price target on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday. TheStreet upgraded Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Down 1.4 %

Shares of KNSA stock traded down $0.25 during mid-day trading on Thursday, hitting $17.61. 477,276 shares of the stock were exchanged, compared to its average volume of 404,181. Kiniksa Pharmaceuticals has a 52-week low of $10.65 and a 52-week high of $22.09. The firm has a fifty day moving average of $19.32 and a 200 day moving average of $18.00. The company has a market cap of $1.24 billion, a PE ratio of 163.38 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The company had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The business's quarterly revenue was up 65.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.18) EPS.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, CEO Sanj K. Patel sold 5,582 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total transaction of $117,222.00. Following the transaction, the chief executive officer now owns 65,012 shares in the company, valued at $1,365,252. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sanj K. Patel sold 5,582 shares of the company's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total value of $117,222.00. Following the sale, the chief executive officer now owns 65,012 shares in the company, valued at approximately $1,365,252. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock worth $709,929 in the last ninety days. Insiders own 54.23% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in KNSA. Altitude Crest Partners Inc. acquired a new position in Kiniksa Pharmaceuticals during the 4th quarter worth approximately $7,999,000. Acadian Asset Management LLC increased its stake in Kiniksa Pharmaceuticals by 916.6% in the third quarter. Acadian Asset Management LLC now owns 226,181 shares of the company's stock valued at $3,919,000 after purchasing an additional 203,933 shares during the last quarter. Granahan Investment Management LLC lifted its position in Kiniksa Pharmaceuticals by 35.2% in the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company's stock valued at $12,671,000 after acquiring an additional 188,174 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals by 180.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 208,500 shares of the company's stock valued at $3,622,000 after purchasing an additional 134,070 shares during the period. Finally, EAM Investors LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $2,161,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.